Association of Hyperhomocysteinemia with Increased Coronary Microcirculatory Resistance and Poor Short-Term Prognosis of Patients with Acute Myocardial Infarction after Elective Percutaneous Coronary Intervention
Table 4
Determination of risk factors for MACE at three months after PCI.
Univariate regression analysis
Logistic regression analysis
MACE (n = 16)
None-MACE (n = 95)
X2 (t)
B
r
OR
Age
57.5 ± 9.6
52.0 ± 10.8
0.996
0.041
0.769
0.297
2.652
0.031
Male
10 (62.5%)
48 (50.5%)
0.787
0.375
Smoker
7 (43.8%)
34 (35.8%)
0.373
0.542
Hypertension
8 (50.0%)
32 (33.7%)
1.314
0.252
Diabetes mellitus
5 (31.3%)
30 (31.6%)
0.001
0.979
Dyslipidemia
7 (43.8%)
39 (41.1%)
0.041
0.839
BMI ≥24 kg/m2
9 (56.3%)
51 (53.7%)
0.036
0.849
CKD
1 (6.3%)
10 (10.5%)
0.280
0.596
Previous PCI
8 (50.0%)
27 (28.4%)
2.954
0.086
Calcium-blocker
8 (50.0%)
36 (37.9%)
0.839
0.360
Beta-blocker
10 (62.5%)
63 (66.3%)
0.089
0.766
ACEI/ARB
10 (62.5%)
51 (53.7%)
0.430
0.512
Nitrates
11 (68.8%)
51 (53.7%)
1.261
0.262
Statins
15 (93.8%)
94 (98.9%)
2.091
0.148
EF
42.9 ± 5.0
52.5 ± 6.5
5.63
<0.01
0.986
0.389
4.986
0.022
Hcy
15.32 ± 4.93
9.70 ± 3.96
−5.004
<0.01
0.805
0.324
3.741
0.029
MACE: major adverse cardiovascular events. BMI: body mass index; CKD: chronic kidney diseases; PCI: percutaneous coronary intervention; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; EF: ejection fraction; Hcy: homocysteine.
